Free Trial
→ Satellite Images Spot Potential $10 Trillion Discovery (From Altimetry) (Ad)tc pixel
NASDAQ:CRBU

Caribou Biosciences Q1 2026 Earnings Report

Caribou Biosciences logo
$1.94 +0.02 (+0.78%)
As of 12:02 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Caribou Biosciences EPS Results

Actual EPS
N/A
Consensus EPS
-$0.33
Beat/Miss
N/A
One Year Ago EPS
N/A

Caribou Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
$2.21 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Caribou Biosciences Announcement Details

Quarter
Q1 2026
Date
5/14/2026
Time
Before Market Opens
Conference Call Date
Friday, May 15, 2026
Conference Call Time
4:00PM ET

Conference Call Resources

Caribou Biosciences Earnings Headlines

Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference
May 5 at 4:05 PM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/05/3288251/0/en/caribou-biosciences-to-participate-in-the-bofa-securities-2026-health-care-conference.html
Caribou Biosciences (CRBU) price target decreased by 22.79% to 8.92
April 28, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/caribou-biosciences-crbu-price-target-decreased-by-22-79-to-8-92/ar-AA21WJ4a
A U.S. Resource Gap Is a National Issue - and Opportunity
America still does not domestically produce one mineral tied to batteries, energy storage, and national defense - and that supply gap may be turning into an opportunity. One domestic supplier appears to have identified that gap early and moved to capitalize on it before the broader market took notice.tc pixel
May 6 at 1:00 AM  |  i2i Marketing Group, LLC (Ad)
Caribou rises on FDA RMAT designation for CAR-T therapy
April 1, 2026  |  seekingalpha.comhttps://seekingalpha.com/news/4570660-caribou-rises-fda-rmat-designation
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
March 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/03/31/3265437/0/en/caribou-biosciences-announces-the-fda-granted-regenerative-medicine-advanced-therapy-rmat-designation-to-cb-011-an-allogeneic-anti-bcma-car-t-cell-therapy.html
Leerink Partners Remains a Buy on Caribou Biosciences (CRBU)
March 11, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/CRBU/pressreleases/623687/leerink-partners-remains-a-buy-on-caribou-biosciences-crbu/
See More Caribou Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Caribou Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Caribou Biosciences and other key companies, straight to your email.

About Caribou Biosciences

Caribou Biosciences (NASDAQ:CRBU) is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology. The company holds licenses to foundational CRISPR intellectual property from the University of California, enabling continuous innovation in genome engineering. Since completing its initial public offering in August 2021, Caribou has focused on progressing its clinical pipeline and expanding manufacturing capabilities to support its growing roster of investigational therapies.

Caribou’s leadership team combines deep expertise in molecular biology, clinical development and manufacturing scale-up, supported by an advisory board that includes leading figures in biotechnology and medicine. The company has established strategic collaborations with pharmaceutical and academic partners to advance its research programs and accelerate clinical translation. Caribou continues to conduct trials across multiple regions, aiming to bring its next-generation cell therapies and in vivo gene-editing treatments to patients worldwide.

View Caribou Biosciences Profile
Earnings Tools